A recent Chinese open-label randomized trial investigated the use of recombinant human granulocyte colony stimulating factor (rh-GCSF) combined with low dose decitabine (5 mg/m2 for 5 days) versus no intervention in 204 patients with high-risk AML in the post allo-HCT setting [27]. The gene discussed is CSF3; the disease is acute myeloid leukemia.